ASXNotification of cessation of securities - NUZ
other announcement
NUZ
Pharmaceuticals, Biotechnology & Life Sciences
Neurizon Therapeutics
- Short interest
- 0.01%
- −0.02 pp 30d
- as of 27 Dec 2024
- Reported shorts
- 43.4K
- Shares on issue
- 491.906M
Neurizon Therapeutics (NUZ) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Updated Investor Presentation and Webinar Reminder
other announcement
FDA Type C Feedback, HEALEY trial potentially registrational
other announcement
Dr Chris Bremer commences as Neurizon CEO
other announcement
StockheadLong Shortz with Neurizon Therapeutics: Setting the stage for NUZ-001’s next phase
Neurizon Therapeutics is gearing up for a pivotal period in the development of NUZ-001. ... Read More The post Long Shortz with Neurizon Therapeutics: Setting the stage for NUZ-001’s next phase appeared first on Stockhead.
Change of Director's Interest Notice
director_dealing announcement
Notification of cessation of securities - NUZ
other announcement
Neurizon Announces Partial Redemption of Convertible Notes
other announcement
Application for quotation of securities - NUZ
other announcement
NIH funds Expanded Access Program for NUZ-001 in ALS
other announcement
StockTake: Pharma veteran takes the Neurizon helm
Tylah Tully looks at a new CEO appointment in pharmaceutical veteran Dr Chris Bremer to lead the biotech through its ... Read More The post StockTake: Pharma veteran takes the Neurizon helm appeared first on Stockhead.
Neurizon Appoints Chief Executive Officer
other announcement
Elanco representative appointed as Neurizon Board Observer
other announcement
Neurizon Completes Initial Drawdown under R&D Facility
other announcement
HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
other announcement
KalkineNeurizon Therapeutics (ASX:NUZ) Reaches Key ALS Trial Milestone
Highlights Neurizon Therapeutics has passed the halfway dosing milestone in its international HEALEY ALS Platform Trial. Recruitment has progressed faster than expected, leading organisers to expand the treatment arm to include additional participants. The milestone marks continued operational progress as the company advances development of its lead therapy for amyotrophic lateral sclerosis. Neurizon Therapeutics Ltd (ASX:NUZ) has achieved a significant clinical devel...
New NUZ-001 Mechanistic Data Presented at BIO 2026
other announcement
Neurizon executes long-term supply agreement with Elanco
other announcement
HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
other announcement
Webinar presentation - Regimen I expands to 240 participants
other announcement
HEALEY ALS Trial Regimen I Expands to 240 Participants
other announcement
Ethics Approval Received for NUZ-001 Oral Liquid P1 Study
other announcement
Australian Microcap Investment Conference Presentation
other announcement
Neurizon Strengthens Board for the Next Growth Phase
other announcement
NUZ-001 Data Shows Multi-Pathway Protein Clearance
other announcement
Change of Director's Interest Notices x4
director_dealing announcement
Neurizon presents at HEALEY ALS Platform Trial Webinar
other announcement
Preclinical Data in Huntington's Disease Presented at ASENT
other announcement